STRIKEMOX™ CV 625 LB

Amoxycillin is a broad-spectrum beta-lactam antibiotic that works by inhibiting bacterial cell wall synthesis. It binds to penicillin-binding proteins (PBPs) located inside the bacterial cell wall, blocking the cross-linking of peptidoglycan chains — a process essential for cell wall integrity. Without a functional cell wall, bacteria are unable to maintain osmotic pressure and undergo rapid lysis and death.

Potassium Clavulanate is a beta-lactamase inhibitor with negligible antibacterial activity on its own. Many resistant bacterial strains produce beta-lactamase enzymes that destroy amoxycillin before it can act. Clavulanate irreversibly binds to these enzymes, neutralising them and restoring amoxycillin's full bactericidal potency. This combination is especially effective against beta-lactamase-producing strains of Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, and Escherichia coli.

Lactic Acid Bacillus (LB) is a probiotic component added to restore and maintain the natural gut flora, which is frequently disrupted during antibiotic therapy. LB colonises the intestinal tract and competes with pathogenic organisms for nutrients and adhesion sites, reducing the incidence of antibiotic-associated diarrhoea and gastrointestinal discomfort. Together, these three components provide broad-spectrum antibacterial cover with enhanced tolerability.

STRIKEMOX™ CV 625 LB is clinically indicated for the treatment of a wide range of bacterial infections caused by susceptible organisms, particularly those involving beta-lactamase-producing strains. The probiotic component makes it especially suitable for patients prone to antibiotic-associated gut disturbance.

Primary indications include:

Upper Respiratory Tract Infections: Acute bacterial sinusitis, otitis media, pharyngitis, tonsillitis, and laryngitis caused by H. influenzae, M. catarrhalis, and S. pneumoniae.

Lower Respiratory Tract Infections: Community-acquired pneumonia, acute exacerbations of chronic bronchitis, and bronchopneumonia where beta-lactamase-producing organisms are suspected.

Dental and Oral Infections: Periapical abscess, periodontitis, and post-extraction infections where mixed aerobic and anaerobic flora is involved.

Urinary Tract Infections: Cystitis, pyelonephritis, and urethritis caused by susceptible gram-negative organisms including E. coli and Klebsiella species.

Skin and Soft Tissue Infections: Cellulitis, wound infections, abscesses, and impetigo caused by S. aureus and Streptococcus pyogenes.

Gastrointestinal Infections: Intra-abdominal infections and Helicobacter pylori-associated conditions when used as part of a combination regimen.

The addition of Lactic Acid Bacillus specifically addresses the clinical concern of antibiotic-associated diarrhoea, making this formulation preferred in patients with a history of gastrointestinal sensitivity.

Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.